Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06032949 · ClinicalTrials.gov registry record · NA
Vialize Use for the Reduction of Vascular Groin Incisional Dehiscence and Infection
A NA study of Vascular Diseases, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06032949: Completed NA study of Vascular Diseases, sponsored by University of Florida.
NCT06032949 is a NA study of Vascular Diseases that has completed, run by University of Florida. The registered enrollment target is 50 participants, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06032949, a NA study of Vascular Diseases, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. Prior attempts at reducing this complication rate have been largely unsuccessful. The purpose of this study is to determine the feasibility of routine Vialize use for vascular surgeries involving a groin incision and to determine the rates of surgical site infection/dehiscence in such patients receiving subcutaneous Vialize.
Primary Outcome
Aim 1
Conditions Studied
Interventions
- OTHER Vialize
Study Locations (1)
Florida
- UF Health Heart & Vascular Hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2025-02-28 |
| Phase | NA |
What the finished NCT06032949 record still lists
NCT06032949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Vialize is the first listed.
NCT06032949 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06032949 about?
NCT06032949 is a clinical study titled "Vialize Use for the Reduction of Vascular Groin Incisional Dehiscence and Infection". Groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. Prior attempts at reducing this complication rate have been largely unsuccessful. The purpose of this study is to determine the feasibility...
What is the current status of trial NCT06032949?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2023-10-23. Estimated completion is 2025-02-28.
What conditions does trial NCT06032949 study?
This clinical trial studies the following conditions: Vascular Diseases.
What interventions are being tested in trial NCT06032949?
The interventions under investigation include: Vialize (OTHER).
Who is sponsoring clinical trial NCT06032949?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06032949 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06032949's enrollment target sits among peer trials
50 34th of 40 higher than 5 of 40 other Vascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
-
SPYRAL GEMINI Pilot Study
RECRUITING · NA
-
Passive Limb Movement Study
RECRUITING · NA
-
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI